This article was originally published in The Gray Sheet
Executive SummaryNext generation Cyberonics NeuroCybernetic Prosthesis (NCP) vagus nerve stimulator for treatment of epilepsy will feature Microsemi's custom integrated circuits, following a long-term licensing deal announced by the firms May 30. Microsemi's "system-on-chip" will allow the new version to be programmable. The beefed-up device will be tested in depression, anxiety, Alzheimer's, obesity, cardiac arrhythmia, and pain, firm says
You may also be interested in...
The risk of developing meningioma with cyproterone-containing medicines is rare, but it is serious enough to merit restrictions on how such products are used, according to the European Medicines Agency.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.